Literature DB >> 7694681

Persistence of human multilineage, self-renewing lymphohematopoietic stem cells in chimeric sheep.

E F Srour1, E D Zanjani, K Cornetta, C M Traycoff, A W Flake, M Hedrick, J E Brandt, T Leemhuis, R Hoffman.   

Abstract

We have previously reported the ability of uncharacterized human bone marrow (BM) cells to engraft into preimmune fetal sheep, thereby creating sheep-human chimera suitable for in vivo examination of the properties of human hematopoietic stem cells (HSC). Adult human bone marrow CD34+ HLA-DR- cells have been extensively characterized in vitro and have been demonstrated to contain a number of primitive hematopoietic progenitor cells (PHPC). However, the capacity of such highly purified populations of human marrow CD34+ HLA-DR- cells to undergo in vivo self-renewal and multipotential lymphohematopoietic differentiation has not been previously demonstrated. To achieve that, human CD34+ HLA-DR- cells were transplanted in utero into immunoincompetent fetal sheep to investigate the BM-populating potential of these cells. Long-term chimerism, sustained human hematopoiesis, and expression of human cells belonging to all human blood cell lineages were demonstrated in two animals for more than 7 months' posttransplantation. Chimeric BM contained erythroid, granulocytic/monocytic, and megakaryocytic hematopoietic progenitor cells, as well as the primitive high proliferative potential colony-forming cell (HPP-CFC). Under a variety of in vitro experimental conditions, chimeric BM cells gave rise to human T cells expressing T-lymphocyte-specific markers, human natural killer (NK) cells, and human IgG-producing B cells. In vivo expansion and possibly self-renewal of transplanted PHPC was confirmed by the detection in chimeric BM 130 days' posttransplantation of CD34+ HLA-DR- cells, the phenotype of human cells constituting the stem-cell graft. These studies demonstrate not only the BM-populating capacity, multipotential differentiation, and most likely self-renewal capabilities of human CD34+ HLA-DR- cells, but also that this BM population contains human HSC. Furthermore, it appears that this animal model of xenogeneic stem-cell transplantation is extremely useful for in vivo examination of human hematopoiesis and the behavioral and functional characteristics of human HSC.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7694681

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

Review 1.  The biological basis of and strategies for clinical xenotransplantation.

Authors:  T E Starzl; L A Valdivia; N Murase; A J Demetris; P Fontes; A S Rao; R Manez; I R Marino; S Todo; A W Thomson
Journal:  Immunol Rev       Date:  1994-10       Impact factor: 12.988

2.  Consequences of human stem cells taking up residence in sheep.

Authors:  H E Broxmeyer
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

3.  Toward development and production of human T cells in swine for potential use in adoptive T cell immunotherapy.

Authors:  Brenda M Ogle; Bruce E Knudsen; Ryuta Nishitai; Kiyoshi Ogata; Jeffrey L Platt
Journal:  Tissue Eng Part A       Date:  2009-05       Impact factor: 3.845

4.  Mouse fetal and embryonic liver cells differentiate human umbilical cord blood progenitors into CD56-negative natural killer cell precursors in the absence of interleukin-15.

Authors:  Valarie McCullar; Robert Oostendorp; Angela Panoskaltsis-Mortari; Gong Yun; Charles T Lutz; John E Wagner; Jeffrey S Miller
Journal:  Exp Hematol       Date:  2008-03-04       Impact factor: 3.084

5.  C1qRp defines a new human stem cell population with hematopoietic and hepatic potential.

Authors:  Guenahel H Danet; Jennifer L Luongo; Gary Butler; Min Min Lu; Andrea J Tenner; M Celeste Simon; Dominique A Bonnet
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-24       Impact factor: 11.205

6.  Further phenotypic characterization of the primitive lineage- CD34+CD38-CD90+CD45RA- hematopoietic stem cell/progenitor cell sub-population isolated from cord blood, mobilized peripheral blood and patients with chronic myelogenous leukemia.

Authors:  D Wisniewski; M Affer; J Willshire; B Clarkson
Journal:  Blood Cancer J       Date:  2011-09-30       Impact factor: 11.037

Review 7.  Experimental and clinical progress of in utero hematopoietic cell transplantation therapy for congenital disorders.

Authors:  Chunyu Shi; Lu Pan; Zheng Hu
Journal:  Front Pharmacol       Date:  2022-09-02       Impact factor: 5.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.